 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aptevo announced the pricing of a public offering of 3,400,000 shares of its common stock or pre-funded warrants in lieu thereof and warrants to purchase up to an aggregate of 6,800,000 shares of its...

Why Aptevo Therapeutics Stock Is Cratering

StockNews.com assumed coverage on shares of Aptevo Therapeutics (NASDAQ:APVO - Free Report) in a research report report published on Tuesday morning. The brokerage issued a hold rating on the...

Aptevo Therapeutics (NASDAQ:APVO) Earns Hold Rating from Analysts at StockNews.com

SEATTLE, WA / ACCESSWIRE / March 18, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its...

Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference

StockNews.com assumed coverage on shares of Aptevo Therapeutics (NASDAQ:APVO  Free Report) in a research note released on Sunday. The firm issued a hold rating on the biotechnology...

Aptevo Therapeutics (NASDAQ:APVO) Now Covered by Analysts at StockNews.com

Aptevo Therapeutics, Immuron, CASI Pharmaceuticals among healthcare movers...

Aptevo Therapeutics, Immuron, CASI Pharmaceuticals among healthcare movers

Interim results from the Phase 1 trial of ALG.APV-527 by Alligator Bioscience and Aptevo Therapeutics. Positive signs of clinical activity in breast cancer patients, with well-tolerated treatment and...

Why Is Immuno-Oncology Focused Aptevo Therapeutics Stock Trading Higher On Thursday?

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Aptevo Therapeutics trading resumes

Aptevo Therapeutics trading halted, volatility trading pause

Initial interim data show favorable drug exposure and confirm ALG.APV-527 biological activityEarly promising signs of clinical activity in heavily pretreated patientsDose-escalation trial data on...

Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4

This is a Bearish indicator signaling APVO's price could decline from here. Traders may explore shorting the stock or put options...

Aptevo Therapeutics (APVO, $5.69) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 5, 2024

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded in February 2016 and is headquartered in Seattle, WA.

Volume (M)	238,130.00
52-Wk High	$91.96
52-Wk Low	$0.70

APVO Aptevo Therapeutics Inc

About

Feed

News

Sentiment

Fundamentals